Emily A. Vucic

Zephyr Software (United States) — United States

Biochemistry, Genetics and Molecular Biology · Life Sciences

29h-index3.2kcitations111works0.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

RNA modifications and cancer(24), Epigenetics and DNA Methylation(19), Cancer-related gene regulation(17), Cancer Immunotherapy and Biomarkers(16), Biological Research and Disease Studies(14)

Publications111 total

Abstract 4640: Identifying novel drivers of drug sensitivity using an AI-enabled composite biomarker - osimertinib sensitivity beyond EGFR
Cancer Research·2025
A Closer Look At A Rare Anomaly: Case Series Of Anomalous Coronary Artery From The Non-coronary Cusp
Journal of cardiovascular computed tomography·2024
Evaluation of a novel signature for PARP inhibitor sensitivity prediction using real-world data.
Journal of Clinical Oncology·2024
1295 Integrating drug structure and target binding affinity for improved prediction of survival in cancer patients treated with immune checkpoint inhibitors
Regular and Young Investigator Award Abstracts·2023Open Access
Delineating spatial cell-cell interactions in the solid tumour microenvironment through the lens of highly multiplexed imaging
Frontiers in Immunology·2023· 8 citedOpen Access
Methionine-producing tumor micro(be) environment fuels growth of solid tumors
Cellular Oncology·2023· 15 citedOpen Access
Use of a systems-biology informed machine learning model to predict drug response using clinically available NGS data.
Journal of Clinical Oncology·2023· 2 cited
Figure S2 from Tumor Cell–Derived IL1β Promotes Desmoplasia and Immune Suppression in Pancreatic Cancer
2023Open Access
Figure S3 from Tumor Cell–Derived IL1β Promotes Desmoplasia and Immune Suppression in Pancreatic Cancer
2023Open Access
Data from Tumor Cell–Derived IL1β Promotes Desmoplasia and Immune Suppression in Pancreatic Cancer
2023Open Access
Figure S5 from Tumor Cell–Derived IL1β Promotes Desmoplasia and Immune Suppression in Pancreatic Cancer
2023Open Access
Figure S5 from Tumor Cell–Derived IL1β Promotes Desmoplasia and Immune Suppression in Pancreatic Cancer
2023Open Access
Figure S3 from Tumor Cell–Derived IL1β Promotes Desmoplasia and Immune Suppression in Pancreatic Cancer
2023Open Access
Supplementary Methods from Tumor Cell–Derived IL1β Promotes Desmoplasia and Immune Suppression in Pancreatic Cancer
2023Open Access
Figure S6 from Tumor Cell–Derived IL1β Promotes Desmoplasia and Immune Suppression in Pancreatic Cancer
2023Open Access
Data from Tumor Cell–Derived IL1β Promotes Desmoplasia and Immune Suppression in Pancreatic Cancer
2023Open Access
Figure S2 from Tumor Cell–Derived IL1β Promotes Desmoplasia and Immune Suppression in Pancreatic Cancer
2023Open Access
Figure S1 from Tumor Cell–Derived IL1β Promotes Desmoplasia and Immune Suppression in Pancreatic Cancer
2023Open Access
Figure S4 from Tumor Cell–Derived IL1β Promotes Desmoplasia and Immune Suppression in Pancreatic Cancer
2023Open Access
Figure S1 from Tumor Cell–Derived IL1β Promotes Desmoplasia and Immune Suppression in Pancreatic Cancer
2023Open Access
page 1 of 6Next →

Frequent Co-authors

Wan L. Lam(45), Kelsie L. Thu(21), Stephen Lam(17), Victor D. Martínez(16), Calum MacAulay(11), William W. Lockwood(10), Larissa A. Pikor(10), Raj Chari(9), Daiana D. Becker‐Santos(8), Adi F. Gazdar(8), Stephen Lam(8), Katey S.S. Enfield(7), Carolyn J. Brown(7), John C. English(6), Ian M. Wilson(6), Greg L. Stewart(5), Jennifer Y. Kennett(5), Roland Hubaux(5), John Yee(5), Igor Jurišica(5)